DrugPipeline.net has announced the addition of “Meniere Disease - Pipeline Review, H2 2017” research report to their website www.DrugPipeline.net
Bangalore, India -- (SBWIRE) -- 10/18/2017 -- Meniere Disease - Pipeline Review, H2 2017, provides an overview of the Meniere Disease (Ear Nose Throat Disorders) pipeline landscape.
Meniere disease is a disorder of the inner ear that causes spontaneous episodes of vertigo. Signs and symptoms of Meniere disease are hearing loss, tinnitus and feeling of fullness in the ear. Causes include allergies, viral infection, head trauma and migraines.
Meniere Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Meniere Disease (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Meniere Disease (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 2 and 1 respectively.
Meniere Disease (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Meniere Disease (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Meniere Disease (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Meniere Disease (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Meniere Disease (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Meniere Disease (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Spanning over 43 pages "Meniere Disease - Pipeline Review, H2 2017" report covers Introduction, Report Coverage, Meniere Disease - Overview, Meniere Disease - Therapeutics Development, Pipeline Overview, Meniere Disease - Therapeutics Assessment, Meniere Disease - Companies Involved in Therapeutics Development, Meniere Disease - Drug Profiles, Product Description, Meniere Disease - Dormant Projects, Appendix. This report Covered Companies - Orbis Biosciences Inc, Otonomy Inc, Quark Pharmaceuticals Inc, Sound Pharmaceuticals Inc, Synphora AB.
For more information Visit at: http://www.drugpipeline.net/global-markets-direct/meniere-disease-pipeline-review-h2-2017
Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017 - Visit at - http://www.drugpipeline.net/global-markets-direct/attention-deficit-hyperactivity-disorder-adhd-pipeline-review-h2-2017
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) – Pipeline Review, H2 2017 - Visit at - http://www.drugpipeline.net/global-markets-direct/c-c-chemokine-receptor-type-5-chemr13-or-hiv-1-fusion-coreceptor-or-cd195-or-0
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.